Does the media refer more to SPRY or ORKA?

In the previous week, Oruka Therapeutics had 2 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 4 mentions for Oruka Therapeutics and 2 mentions for ARS Pharmaceuticals. Oruka Therapeutics' average media sentiment score of 1.11 beat ARS Pharmaceuticals' score of 0.93 indicating that Oruka Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ARS Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oruka Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BEAM or SPRY?

In the previous week, Beam Therapeutics had 2 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 4 mentions for Beam Therapeutics and 2 mentions for ARS Pharmaceuticals. Beam Therapeutics' average media sentiment score of 0.96 beat ARS Pharmaceuticals' score of 0.93 indicating that Beam Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ARS Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to SPRY or DNLI?

In the previous week, ARS Pharmaceuticals and ARS Pharmaceuticals both had 2 articles in the media. Denali Therapeutics' average media sentiment score of 1.26 beat ARS Pharmaceuticals' score of 0.93 indicating that Denali Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ARS Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Denali Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, TLX or SPRY?

Telix Pharmaceuticals has higher revenue and earnings than ARS Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telix Pharmaceuticals $803.79M 3.69 -$7.12M N/A N/A ARS Pharmaceuticals $98.99M 8.81 -$171.30M -$2.01 N/A

Does the media prefer TLX or SPRY?

In the previous week, Telix Pharmaceuticals had 2 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 4 mentions for Telix Pharmaceuticals and 2 mentions for ARS Pharmaceuticals. ARS Pharmaceuticals' average media sentiment score of 0.93 beat Telix Pharmaceuticals' score of 0.38 indicating that ARS Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telix Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ARS Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

ARS Pharmaceuticals (SPRY) Competitors

$8.78 -0.12 (-1.34%)

As of 02:50 PM Eastern

Compare

SPRY vs. ORKA, OGN, BEAM, DNLI, and TLX

Should you buy ARS Pharmaceuticals stock or one of its competitors? MarketBeat compares ARS Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ARS Pharmaceuticals include Oruka Therapeutics (ORKA), Organon & Co. (OGN), Beam Therapeutics (BEAM), Denali Therapeutics (DNLI), and Telix Pharmaceuticals (TLX). These companies are all part of the "pharmaceutical products" industry.

How does ARS Pharmaceuticals compare to Oruka Therapeutics?

ARS Pharmaceuticals (NASDAQ:SPRY) and Oruka Therapeutics (NASDAQ:ORKA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, media sentiment, institutional ownership and dividends.

Oruka Therapeutics has lower revenue, but higher earnings than ARS Pharmaceuticals. Oruka Therapeutics is trading at a lower price-to-earnings ratio than ARS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ARS Pharmaceuticals	$98.99M	8.81	-$171.30M	-$2.01	N/A
Oruka Therapeutics	N/A	N/A	-$105.43M	-$1.94	N/A

Oruka Therapeutics has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -200.00%. Oruka Therapeutics' return on equity of -26.16% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ARS Pharmaceuticals	-200.00%	-153.61%	-60.85%
Oruka Therapeutics	N/A	-26.16%	-25.00%

ARS Pharmaceuticals has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market. Comparatively, Oruka Therapeutics has a beta of -0.26, indicating that its stock price is 126% less volatile than the broader market.

ARS Pharmaceuticals currently has a consensus price target of $28.60, suggesting a potential upside of 225.70%. Oruka Therapeutics has a consensus price target of $131.30, suggesting a potential upside of 125.78%. Given ARS Pharmaceuticals' higher probable upside, research analysts clearly believe ARS Pharmaceuticals is more favorable than Oruka Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

In the previous week, Oruka Therapeutics had 2 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 4 mentions for Oruka Therapeutics and 2 mentions for ARS Pharmaceuticals. Oruka Therapeutics' average media sentiment score of 1.11 beat ARS Pharmaceuticals' score of 0.93 indicating that Oruka Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ARS Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oruka Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

68.2% of ARS Pharmaceuticals shares are held by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are held by institutional investors. 33.8% of ARS Pharmaceuticals shares are held by company insiders. Comparatively, 23.5% of Oruka Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Oruka Therapeutics beats ARS Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does ARS Pharmaceuticals compare to Organon & Co.?

Organon & Co. (NYSE:OGN) and ARS Pharmaceuticals (NASDAQ:SPRY) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, media sentiment, earnings, analyst recommendations, profitability and risk.

In the previous week, ARS Pharmaceuticals had 2 more articles in the media than Organon & Co.. MarketBeat recorded 2 mentions for ARS Pharmaceuticals and 0 mentions for Organon & Co.. ARS Pharmaceuticals' average media sentiment score of 0.93 beat Organon & Co.'s score of 0.93 indicating that ARS Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Organon & Co.	Positive
ARS Pharmaceuticals	Positive

Organon & Co. has a beta of 1.55, suggesting that its share price is 55% more volatile than the broader market. Comparatively, ARS Pharmaceuticals has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market.

Organon & Co. has higher revenue and earnings than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.22B	0.57	$187M	$0.93	14.40
ARS Pharmaceuticals	$98.99M	8.81	-$171.30M	-$2.01	N/A

77.4% of Organon & Co. shares are held by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are held by institutional investors. 1.6% of Organon & Co. shares are held by company insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Organon & Co. presently has a consensus target price of $11.40, suggesting a potential downside of 14.89%. ARS Pharmaceuticals has a consensus target price of $28.60, suggesting a potential upside of 225.70%. Given ARS Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe ARS Pharmaceuticals is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Organon & Co. has a net margin of 3.99% compared to ARS Pharmaceuticals' net margin of -200.00%. Organon & Co.'s return on equity of 99.95% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organon & Co.	3.99%	99.95%	6.22%
ARS Pharmaceuticals	-200.00%	-153.61%	-60.85%

Summary

Organon & Co. beats ARS Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does ARS Pharmaceuticals compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and ARS Pharmaceuticals (NASDAQ:SPRY) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, risk, media sentiment, profitability and institutional ownership.

Beam Therapeutics has higher revenue and earnings than ARS Pharmaceuticals. Beam Therapeutics is trading at a lower price-to-earnings ratio than ARS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	21.64	-$79.99M	-$0.68	N/A
ARS Pharmaceuticals	$98.99M	8.81	-$171.30M	-$2.01	N/A

99.7% of Beam Therapeutics shares are owned by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 3.8% of Beam Therapeutics shares are owned by insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Beam Therapeutics has a net margin of -39.66% compared to ARS Pharmaceuticals' net margin of -200.00%. Beam Therapeutics' return on equity of -29.00% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-39.66%	-29.00%	-22.61%
ARS Pharmaceuticals	-200.00%	-153.61%	-60.85%

In the previous week, Beam Therapeutics had 2 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 4 mentions for Beam Therapeutics and 2 mentions for ARS Pharmaceuticals. Beam Therapeutics' average media sentiment score of 0.96 beat ARS Pharmaceuticals' score of 0.93 indicating that Beam Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ARS Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Beam Therapeutics has a beta of 2.25, meaning that its share price is 125% more volatile than the broader market. Comparatively, ARS Pharmaceuticals has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market.

Beam Therapeutics presently has a consensus target price of $46.83, indicating a potential upside of 59.30%. ARS Pharmaceuticals has a consensus target price of $28.60, indicating a potential upside of 225.70%. Given ARS Pharmaceuticals' higher probable upside, analysts plainly believe ARS Pharmaceuticals is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Beam Therapeutics beats ARS Pharmaceuticals on 14 of the 17 factors compared between the two stocks.

How does ARS Pharmaceuticals compare to Denali Therapeutics?

ARS Pharmaceuticals (NASDAQ:SPRY) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership.

ARS Pharmaceuticals has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 1.03, suggesting that its stock price is 3% more volatile than the broader market.

ARS Pharmaceuticals has higher earnings, but lower revenue than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than ARS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ARS Pharmaceuticals	$98.99M	8.81	-$171.30M	-$2.01	N/A
Denali Therapeutics	$330.53M	9.33	-$512.54M	-$2.88	N/A

68.2% of ARS Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are owned by institutional investors. 33.8% of ARS Pharmaceuticals shares are owned by company insiders. Comparatively, 12.5% of Denali Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Denali Therapeutics has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -200.00%. Denali Therapeutics' return on equity of -52.20% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ARS Pharmaceuticals	-200.00%	-153.61%	-60.85%
Denali Therapeutics	N/A	-52.20%	-43.86%

ARS Pharmaceuticals presently has a consensus price target of $28.60, suggesting a potential upside of 225.70%. Denali Therapeutics has a consensus price target of $34.25, suggesting a potential upside of 76.19%. Given ARS Pharmaceuticals' higher possible upside, equities analysts plainly believe ARS Pharmaceuticals is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Denali Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87

In the previous week, ARS Pharmaceuticals and ARS Pharmaceuticals both had 2 articles in the media. Denali Therapeutics' average media sentiment score of 1.26 beat ARS Pharmaceuticals' score of 0.93 indicating that Denali Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ARS Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Denali Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Denali Therapeutics beats ARS Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does ARS Pharmaceuticals compare to Telix Pharmaceuticals?

Telix Pharmaceuticals (NASDAQ:TLX) and ARS Pharmaceuticals (NASDAQ:SPRY) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, earnings, valuation and risk.

Telix Pharmaceuticals currently has a consensus price target of $21.13, suggesting a potential upside of 141.43%. ARS Pharmaceuticals has a consensus price target of $28.60, suggesting a potential upside of 225.70%. Given ARS Pharmaceuticals' higher possible upside, analysts clearly believe ARS Pharmaceuticals is more favorable than Telix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Telix Pharmaceuticals has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -200.00%. Telix Pharmaceuticals' return on equity of 0.00% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
ARS Pharmaceuticals	-200.00%	-153.61%	-60.85%

In the previous week, Telix Pharmaceuticals had 2 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 4 mentions for Telix Pharmaceuticals and 2 mentions for ARS Pharmaceuticals. ARS Pharmaceuticals' average media sentiment score of 0.93 beat Telix Pharmaceuticals' score of 0.38 indicating that ARS Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telix Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ARS Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Telix Pharmaceuticals has higher revenue and earnings than ARS Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$803.79M	3.69	-$7.12M	N/A	N/A
ARS Pharmaceuticals	$98.99M	8.81	-$171.30M	-$2.01	N/A

68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 33.8% of ARS Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Telix Pharmaceuticals has a beta of -0.11, suggesting that its share price is 111% less volatile than the broader market. Comparatively, ARS Pharmaceuticals has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market.

Summary

Telix Pharmaceuticals beats ARS Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

Get ARS Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SPRY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SPRY vs. The Competition

Export

Metric	ARS Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$874.96M	$2.91B	$6.26B	$12.43B
Dividend Yield	N/A	1.79%	2.69%	5.29%
P/E Ratio	-4.38	17.65	22.42	24.23
Price / Sales	8.81	479.58	548.01	125.38
Price / Cash	N/A	56.38	42.31	57.88
Price / Book	7.57	3.85	9.82	6.71
Net Income	-$171.30M	$75.85M	$3.56B	$337.09M
7 Day Performance	3.31%	-1.80%	-1.17%	0.63%
1 Month Performance	2.58%	21.90%	3.71%	5.15%
1 Year Performance	-39.57%	21.81%	27.28%	34.36%

ARS Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SPRY ARS Pharmaceuticals	2.8576 of 5 stars	$8.78 -1.3%	$28.60 +225.7%	-38.5%	$874.96M	$98.99M	N/A	90	Analyst Upgrade
ORKA Oruka Therapeutics	3.7096 of 5 stars	$55.01 -6.0%	$120.80 +119.6%	+369.2%	$3.53B	N/A	N/A	N/A	Positive News Analyst Forecast
OGN Organon & Co.	2.6951 of 5 stars	$13.37 +0.2%	$11.40 -14.7%	+45.2%	$3.50B	$6.22B	14.37	10,000
BEAM Beam Therapeutics	2.2963 of 5 stars	$31.14 -5.4%	$46.83 +50.4%	+78.9%	$3.39B	$139.74M	N/A	510
DNLI Denali Therapeutics	3.7193 of 5 stars	$20.41 -3.0%	$34.25 +67.8%	+38.6%	$3.34B	N/A	N/A	430	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SPRY) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ARS Pharmaceuticals (SPRY) Competitors

SPRY vs. ORKA, OGN, BEAM, DNLI, and TLX

How does ARS Pharmaceuticals compare to Oruka Therapeutics?

Summary

How does ARS Pharmaceuticals compare to Organon & Co.?

Summary

How does ARS Pharmaceuticals compare to Beam Therapeutics?

Summary

How does ARS Pharmaceuticals compare to Denali Therapeutics?

Summary

How does ARS Pharmaceuticals compare to Telix Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRY vs. The Competition

ARS Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ARS Pharmaceuticals (SPRY) Competitors

SPRY vs. ORKA, OGN, BEAM, DNLI, and TLX

How does ARS Pharmaceuticals compare to Oruka Therapeutics?

Which has better earnings & valuation, SPRY or ORKA?

Is SPRY or ORKA more profitable?

Which has more volatility & risk, SPRY or ORKA?

Do analysts prefer SPRY or ORKA?

Does the media refer more to SPRY or ORKA?

Do insiders and institutionals hold more shares of SPRY or ORKA?

Summary

How does ARS Pharmaceuticals compare to Organon & Co.?

Does the media favor OGN or SPRY?

Which has more risk and volatility, OGN or SPRY?

Which has stronger valuation & earnings, OGN or SPRY?

Do insiders & institutionals have more ownership in OGN or SPRY?

Do analysts prefer OGN or SPRY?

Is OGN or SPRY more profitable?

Summary

How does ARS Pharmaceuticals compare to Beam Therapeutics?

Which has better earnings and valuation, BEAM or SPRY?

Do institutionals & insiders believe in BEAM or SPRY?

Is BEAM or SPRY more profitable?

Does the media prefer BEAM or SPRY?

Which has more volatility and risk, BEAM or SPRY?

Do analysts recommend BEAM or SPRY?

Summary

How does ARS Pharmaceuticals compare to Denali Therapeutics?

Which has more risk & volatility, SPRY or DNLI?

Which has better valuation and earnings, SPRY or DNLI?

Do institutionals and insiders hold more shares of SPRY or DNLI?

Is SPRY or DNLI more profitable?

Do analysts recommend SPRY or DNLI?

Does the media refer more to SPRY or DNLI?

Summary

How does ARS Pharmaceuticals compare to Telix Pharmaceuticals?

Do analysts rate TLX or SPRY?

Is TLX or SPRY more profitable?

Does the media prefer TLX or SPRY?

Which has stronger earnings and valuation, TLX or SPRY?

Do institutionals and insiders have more ownership in TLX or SPRY?

Which has more risk and volatility, TLX or SPRY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRY vs. The Competition

ARS Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools